All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AG019
Therapeutic Area: Endocrinology Product Name: AG019
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: JMP Securities
Deal Size: $112.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 22, 2021
Details:
Precigen is currently progressing its Phase 1b/2a study to assess the safety and tolerability of different doses of AG019 administered alone or in combination with teplizumab. Funds will support company's ongoing projects and general corporate purposes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AG019
Therapeutic Area: Endocrinology Product Name: AG019
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2020
Details:
The study met its primary endpoint demonstrating safety and tolerability. No serious or severe TEAEs were reported in any of the patients treated with AG019 monotherapy, and no patient discontinued treatment.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
